Literature DB >> 34958184

Updated picture of SARS-CoV-2 variants and mutations.

Giuseppe Lippi1, Camilla Mattiuzzi2, Brandon M Henry3,4.   

Abstract

The worldwide burden of coronavirus disease 2019 (COVID-19) is still unremittingly prosecuting, with nearly 300 million infections and over 5.3 million deaths recorded so far since the origin of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic at the end of the year 2019. The fight against this new highly virulent beta coronavirus appears one of the most strenuous and long challenges that humanity has ever faced, since a definitive treatment has not been identified so far. The adoption of potentially useful physical preventive measures such as lockdowns, social distancing and face masking seems only partially effective for mitigating viral spread, though efficacy and continuation of such measures on the long term is questionable, due to many social and economic reasons. Many COVID-19 vaccines have been developed and are now widely used, though their effectiveness is challenged by several aspects such as low uptake and limited efficacy in some specific populations, as well as by continuous emergence of new mutations in the SARS-CoV-2 genome, accompanying the origin and spread of new variants, which in turn may contribute to further decrease the effectiveness of current vaccines and treatments. This article is hence aimed to provide an updated picture of SARS-CoV-2 variants and mutations that have emerged from November 2019 to present time (i.e., early December 2021).
© 2021 Walter de Gruyter GmbH, Berlin/Boston.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; mutations; variants

Mesh:

Substances:

Year:  2021        PMID: 34958184     DOI: 10.1515/dx-2021-0149

Source DB:  PubMed          Journal:  Diagnosis (Berl)        ISSN: 2194-802X


  19 in total

1.  Evolution of SARS-CoV-2 in Spain during the First Two Years of the Pandemic: Circulating Variants, Amino Acid Conservation, and Genetic Variability in Structural, Non-Structural, and Accessory Proteins.

Authors:  Paloma Troyano-Hernáez; Roberto Reinosa; África Holguín
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

2.  Most frequently harboured missense variants of hACE2 across different populations exhibit varying patterns of binding interaction with spike glycoproteins of emerging SARS-CoV-2 of different lineages.

Authors:  Anika Tahsin; Rubaiat Ahmed; Piyash Bhattacharjee; Maisha Adiba; Abdullah Al Saba; Tahirah Yasmin; Sajib Chakraborty; A K M Mahbub Hasan; A H M Nurun Nabi
Journal:  Comput Biol Med       Date:  2022-07-20       Impact factor: 6.698

Review 3.  Molecular and Clinical Investigation of COVID-19: From Pathogenesis and Immune Responses to Novel Diagnosis and Treatment.

Authors:  Narjes Riahi Kashani; Javid Azadbakht; Hassan Ehteram; Hamed Haddad Kashani; Hassan Rajabi-Moghadam; Ejaz Ahmad; Hossein Nikzad; Elahe Seyed Hosseini
Journal:  Front Mol Biosci       Date:  2022-05-19

Review 4.  LumiraDX SARS-CoV-2 Antigen Test for Diagnosing Acute SARS-CoV-2 Infection: Critical Literature Review and Meta-Analysis.

Authors:  Giuseppe Lippi; Brandon M Henry; Mario Plebani
Journal:  Diagnostics (Basel)       Date:  2022-04-11

Review 5.  FebriDx for rapid screening of patients with suspected COVID-19 upon hospital admission: systematic literature review and meta-analysis.

Authors:  G Lippi; R Nocini; C Mattiuzzi; B M Henry
Journal:  J Hosp Infect       Date:  2022-02-21       Impact factor: 8.944

6.  Analysis of online search trends suggests that SARS-CoV-2 Omicron (B.1.1.529) variant causes different symptoms.

Authors:  Giuseppe Lippi; Riccardo Nocini; Brandon M Henry
Journal:  J Infect       Date:  2022-02-17       Impact factor: 38.637

7.  Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD.

Authors:  Qianqian Li; Mengyi Zhang; Ziteng Liang; Li Zhang; Xi Wu; Chaoying Yang; Yimeng An; Jincheng Tong; Shuo Liu; Tao Li; Qianqian Cui; Jianhui Nie; Jiajing Wu; Weijin Huang; Youchun Wang
Journal:  MedComm (2020)       Date:  2022-04-09

8.  COVID-19 vaccines efficacy in preventing or limiting SARS-CoV-2 infections.

Authors:  Camilla Mattiuzzi; Giuseppe Lippi
Journal:  J Infect       Date:  2022-01-31       Impact factor: 38.637

9.  The presence of anti-SARS-CoV-2 antibodies does not necessarily reflect efficient neutralization.

Authors:  Giuseppe Lippi; Mario Plebani
Journal:  Int J Infect Dis       Date:  2022-01-31       Impact factor: 12.074

10.  COVID-19 vaccination and SARS-CoV-2 Omicron (B.1.1.529) variant: a light at the end of the tunnel?

Authors:  Camilla Mattiuzzi; Brandon M Henry; Giuseppe Lippi
Journal:  Int J Infect Dis       Date:  2022-03-09       Impact factor: 12.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.